Health-related quality of life in relapsed/refractory multiple myeloma treated with melflufen and dexamethasone: analyses from the phase III OCEAN study
Haematologica. 2024 Feb 29.
doi: 10.3324/haematol.2023.284635.
Online ahead of print.
1 Oslo Myeloma Center, Department of Hematology, Oslo University Hospital and KG Jebsen Center for B Cell Malignancies, University of Oslo, Oslo, Norway. fredrikschjesvold@gmail.com.
2 Department of Medicine I, Center for Medical Oncology and Hematology with Outpatient Department and Palliative Care, Wilhelminen Cancer Research Institute, Vienna.
3 Bone Marrow Transplantation Unit and Department of Hematology, Evangelismos Hospital, Athens, Greece.
4 Department of Hemato-Oncology, University Hospital Ostrava, Ostrava, Czech Republic.
5 University of Medicine and Pharmacy "Carol Davila", Center of Hematology and Bone Marrow Transplantation, Fundeni Clinical Institute, Bucharest, Romania.
6 Department of Hemato-Oncology and Bone Marrow Transplantation, Medical University of Lublin.
7 Department of Internal Medicine, Hematology and Oncology, University Hospital Brno, Babak Myeloma Group, Faculty of Medicine, Masaryk University, Brno, Czech Republic.
8 1st Department of Medicine - Department of Hematology, First Faculty of Medicine, Charles University and General Hospital in Prague, Prague, Czech Republic.
9 Department of Clinical Therapeutics, National and Kapodistrian University of Athens School of Medicine, Athens, Greece.
10 Department of Internal Medicine and Haematology, Semmelweis University, Budapest, Hungary.
11 National Research Center for Haematology, Moscow, Russia.
12 Oncopeptides AB, Stockholm, Sweden.
13 Hospital Clínico Universitario de Salamanca/IBSAL/CIC, Salamanca, Spain.